Roche reaffirmed its sales outlook while reporting diagnostics and pharmaceutical results that beat analyst expectations, even as investors questioned its long-term growth trajectory amid impending competition to blockbuster assets. The company also highlighted pipeline urgency, including an FDA decision expected by Dec. 18 for giredestrant and ongoing evaluation of additional late-stage candidates. The report notes that Xolair sales in the third quarter came in below consensus estimates after a US copycat launched, while several top products face generic or biosimilar pressure in the coming years. Roche’s guidance for mid single-digit growth contrasts with analyst concerns about underlying momentum heading into 2027. For biotech peers, the episode reflects how capital markets are re-rating pharma as patent cliffs approach—pushing companies to de-risk pipeline timelines and accelerate evidence packages for label-critical assets.